---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-24-000006"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2024-02-21T23:59:59+00:00"
generated_at: "2026-06-05T21:51:57.207588+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Emergent BioSolutions appoints Joseph C. Papa as President and CEO, replacing interim CEO Haywood Miller

## Summary
- Joseph C. Papa appointed President and CEO effective Feb 21, 2024; succeeds interim CEO Haywood Miller.
- Papa brings over 35 years pharma experience, most recently CEO of Bausch + Lomb (NYSE: BLCO).
- Compensation: $1M base salary, 130% bonus target, $1M sign-on bonus, 1.5M stock options, $8M performance incentive tied to share price.
- Also appointed Class II director with term through 2026 annual meeting.
- Press release emphasizes focus on strengthening balance sheet, returning to growth, and paying down debt.

## SEC filing metadata
- accession: 0001367644-24-000006
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2024-02-21T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764424000006/0001367644-24-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764424000006/ebs-20240220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-24-000006
- JSON: https://secwatch.observer/filing/0001367644-24-000006.json
- Plain text: https://secwatch.observer/filing/0001367644-24-000006.txt

## Key facts
- Executive change
  Joseph C. Papa was appointed as President and CEO at Emergent BioSolutions Inc..
  - Action: appointed
  - Role: President and CEO
  source text: appointed Joseph C. Papa as President and CEO of the Company, effective February 21, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1367644/000136764424000006/0001367644-24-000006-index.htm
- Executive change
  Joseph C. Papa was appointed as Class II director at Emergent BioSolutions Inc..
  - Action: appointed
  - Role: Class II director
  source text: Mr. Papa has been appointed as Class II director of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1367644/000136764424000006/0001367644-24-000006-index.htm
- Executive change
  Haywood Miller departed as Interim CEO at Emergent BioSolutions Inc..
  - Action: stepped down
  - Role: Interim CEO
  source text: Haywood Miller, who will step down from his role as interim CEO of the Company, effective February 21, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1367644/000136764424000006/0001367644-24-000006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.